Communication Dans Un Congrès Année : 2023

CALIPSO: the rise of smart liposomes in cancer treatment

Résumé

Our team iGEM Toulouse tackles the challenge of side effects in cancer treatment with CALIPSO, an intelligent therapeutic liposome. It senses cancer biomarkers, produces the anticancer drug in situ, and delivers it right on the tumor site. By combining in silico protein design, genetic biosensors, cell-free protein synthesis, and biochemical network modeling, we devised an integrated liposomal platform with cell-like functionalities to specifically kill cancer cells. We engaged with a broad spectrum of stakeholders, well beyond scientists, such as supportive care professionals, cancer-fighting associations and patients, ensuring CALIPSO s real-world impact. Moreover, we developed a business strategy to transition our innovative technology into a robust therapeutic startup. We believe CALIPSO has the potential to push the boundaries of chemotherapy by combining the strength of therapeutic liposomes and bottom-up synthetic biology. Using genetically engineered liposomes as a chassis enables a wide array of new applications, which will inspire future iGEM projects.

Fichier non déposé

Dates et versions

hal-04757205 , version 1 (28-10-2024)

Identifiants

  • HAL Id : hal-04757205 , version 1

Citer

Danelon Christophe, Brice Enjalbert, Ambre Jousselin, Pierre Millard, Cédric Y Montanier, et al.. CALIPSO: the rise of smart liposomes in cancer treatment. iGEM 2023, Oct 2023, Paris, France. ⟨hal-04757205⟩
110 Consultations
0 Téléchargements

Partager

  • More